Single Chain Antibody Patents (Class 424/135.1)
  • Patent number: 11492394
    Abstract: Provided herein are containers comprising a composition comprising an antibody comprising a heavy chain comprising SEQ ID NO:1 and a light chain comprising SEQ ID NO:2. The containers can be bottles or vials, for example, glass or polyethylene terephthalate G (PETG) bottles or vials. Also provided are kits comprising the containers and methods of treating cancer using the antibodies from the containers.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: November 8, 2022
    Assignee: Nascent Biotech, Inc.
    Inventor: Ivan Babic
  • Patent number: 11492408
    Abstract: The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: November 8, 2022
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin
  • Patent number: 11472875
    Abstract: The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: October 18, 2022
    Assignee: CYTOMX THERAPEUTICS, INC.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva, Jason Gary Sagert, Jonathan Alexander Terrett, James William West
  • Patent number: 11357822
    Abstract: A method for treating a subject suffering from Alzheimer's disease is provided. The method includes administering to the subject a therapeutically effective amount of lipopolysaccharide-binding protein (LBP). A composition including a therapeutically effective amount of LBP is also provided.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 14, 2022
    Assignee: Stellenbosch University
    Inventors: Etheresia Pretorius, Douglas Bruce Kell
  • Patent number: 11352442
    Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: June 7, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Gregory Moore, John Desjarlais, Seung Y. Chu, Rumana Rashid, Umesh Muchhal
  • Patent number: 11339213
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 24, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar, Robert Joseph Stagg
  • Patent number: 11332521
    Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 17, 2022
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
  • Patent number: 11325982
    Abstract: The present invention relates to bispecific or multi-specific antibody molecules with two or more paratopes. At least one paratope is Fv or scFv, while the other paratope is in a mono-valent or bivalent Fab. These novel molecules also have an Fc moiety that allows extended half-life in vivo.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: May 10, 2022
    Assignees: XUANZHU BIOPHARMACEUTICAL CO., LTD., BEIJING XUANZHU COMBIO CO., LTD.
    Inventors: Shouhua Xiao, Xiaodong Zhu
  • Patent number: 11319376
    Abstract: The present disclosure relates to combination therapy methods of treating a subject having cancer, comprising administering to the subject a) an effective amount of a pharmaceutical composition comprising a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or a pharmaceutically acceptable salt thereof, and b) an effective amount of a pharmaceutical composition comprising a glucagon receptor antagonist.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: May 3, 2022
    Assignee: REMD Biotherapeutics, Inc.
    Inventor: Frank J Calzone
  • Patent number: 11282588
    Abstract: A system writes input data to a storage device as machine-written polynucleotides; and reads machine written polynucleotides from the storage device as output data. The storage device includes a flow cell including a plurality of storage wells in which machine written polynucleotides may be stored. The storage device may include a set of electrodes corresponding to the storage wells that allow for selective interactions with wells across the surface of a flow cell. Operation of the storage device may include receiving a read request associated with a particular location in the storage device, creating a copy of a nucleotide sequence located at the particular location in the storage device, transferring the copy of the nucleotide sequence to a read location, and reading the copy of the nucleotide sequence at the read location.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: March 22, 2022
    Assignee: ILLUMINA, INC.
    Inventors: Craig Ciesla, Ali Agah, Stanley Hong, Tarun Khurana, Aathavan Karunakaran, Arvin Emadi, Merek Siu
  • Patent number: 11267901
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: March 8, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Victor D. Fedorov, Michel Sadelain
  • Patent number: 11234959
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound of the avermectin family, preferably ivermectin, in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of hand eczema.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: February 1, 2022
    Assignee: GALDERMA HOLDING SA
    Inventors: Feriel Hacini-Rachinel, André Jomard, Jean Jacovella, Emmanuel Vial
  • Patent number: 11225521
    Abstract: The present invention is directed to antibodies, including novel antigen binding domains and heterodimeric antibodies, that bind somatostatin receptor 2 (SSTR2).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 18, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Rumana Rashid, Sung-Hyung Lee, Paul Foster
  • Patent number: 11225520
    Abstract: The present invention provides universal immunotherapy compositions useful for targeted treatment of cancers and other immune disorders.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: January 18, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Carl Novina, Robert Distel, Alberto Nobili
  • Patent number: 11219644
    Abstract: Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13 R?2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: January 11, 2022
    Assignee: Baylor College of Medicine
    Inventors: Nabil M. Ahmed, Kevin Bielamowicz, Kristen Fousek
  • Patent number: 11220550
    Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 11, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
  • Patent number: 11192944
    Abstract: The present disclosure provides methods of inducing a complement activity on a surface of a cell comprising contacting the cell with an effective amount of an anti-Factor B antibody, wherein the anti-Factor B antibody inhibits dissociation of a C3bBb complex into a Factor Bb and a C3b.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: December 7, 2021
    Assignee: Bioverativ USA Inc.
    Inventors: Sandip Panicker, Stephen Moore, Pavel A. Nikitin, Tony Byun, Graham Parry
  • Patent number: 11166953
    Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: November 9, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang
  • Patent number: 11155613
    Abstract: The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat or to diagnose a fibrosis and/or a fibrosis-associated disease in a subject in need thereof.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 26, 2021
    Assignee: Neuracle Science Co., Ltd.
    Inventors: Bongcheol Kim, Jae-Keun Lee, Dong Sik Kim
  • Patent number: 11079381
    Abstract: The present invention relates to a method for risk-stratifying subjects suffering from B-precursor acute lymphoblastic leukemia (ALL), wherein said subjects are intended for a therapy comprising administration of a CD3 binding domain. Risk-stratification is based on the determination of the amount blast cells in a bone marrow sample from said subject, and/or on the determination of the number of blast cells per 1 ?l in a CSF sample from said subject. According to the category into which subjects are risk-stratified, said subjects can be appropriately treated, while their risk of a potential adverse neurological reaction can be reduced or even excluded.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 3, 2021
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Gerhard Zugmaier, Peter Kufer, Shilpa Alekar
  • Patent number: 11059906
    Abstract: The present invention provides, among other things, bi-specific molecules including, but not limited to, antibodies, fynomers, aptamers, fusion proteins, and protein binding domains that bind both CCL2 and LOXL2 and uses thereof, in particular, for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions. In some embodiments, the present invention further provides methods and compositions for treatment of scleroderma and related fibrotic and/or inflammatory diseases, disorders and conditions based on the combination of mono-specific anti-CCL2 and anti-LOXL2 molecules.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: July 13, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Paolo G. V. Martini, Madhusudan Natarajan, Patrick Anthony John Haslett, Albert Barnes Seymour
  • Patent number: 11053310
    Abstract: Provided herein are novel anti-EMP2 antibodies useful for the treatment and diagnosis of cancers that express or overexpress EMP2. In one aspect, provided herein is an isolated antibody that binds to Epithelial Membrane Protein 2 (EMP2), that includes heavy chain variable region and a light chain variable region. The heavy chain variable region includes three heavy chain complementary determining regions (HCDRs) and the light chain variable region includes three light chain variable regions (LCDRs). In some embodiments, the sequence of HCDR1 is SEQ ID NO: 11, the sequence of HCDR2 is SEQ ID NO: 12, the sequence of HCDR3 is SEQ ID NO: 13, the sequence of LCDR1 is SEQ ID NO:14, the sequence of LCDR2 is SEQ ID NO: 15, and the sequence of LCDR3 is SEQ ID NO: 16.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 6, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Madhuri Wadehra, Jonathan Braun
  • Patent number: 11041019
    Abstract: The present invention relates to an isolated specific binding molecule which binds human Anx-A1 and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, for each sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cell mediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD), and OCD-related diseases, such as anxiety disorders.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 22, 2021
    Assignee: MEDANNEX LTD.
    Inventors: Henry Charles Wilson Hays, Christopher Barry Wood, Tina Caroline Flatau
  • Patent number: 11014977
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 25, 2021
    Assignees: INSERM (Institut National de al Santé et de la Recherche Médicale), Institut Curie, Université Paus Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Patent number: 11013772
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 25, 2021
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
  • Patent number: 11000601
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: May 11, 2021
    Assignee: OBI PHARMA, INC.
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
  • Patent number: 10975169
    Abstract: The present disclosure provides methods of treating diabetic retinopathy and ocular inflammatory diseases with anti-ceramide antibodies and antibody fragments.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: April 13, 2021
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Richard Kolesnick, Julia Busik
  • Patent number: 10954562
    Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 23, 2021
    Assignee: 10X GENOMICS, INC.
    Inventors: Phillip Belgrader, Josephine Harada, Tarjei Sigurd Mikkelsen, Katherine Pfeiffer, Serge Saxonov, John R. Stuelpnagel
  • Patent number: 10947319
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: March 16, 2021
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Patent number: 10946093
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc.
    Inventor: Melissa Junttila
  • Patent number: 10941199
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson
  • Patent number: 10934362
    Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: March 2, 2021
    Assignee: AMGEN INC.
    Inventors: Gunasekaran Kannan, Ling Liu, Edward J. Belouski, Cen Xu
  • Patent number: 10899829
    Abstract: EMAPII is a monocyte- and endothelial cell-activating protein with prominent pro-apoptotic activity on endothelial and epithelial cells. Provided herein are compositions and methods for treating or preventing endothelial and epithelial apoptosis induced by EMAPII. More particularly, provided herein are compositions and methods for treating or preventing Influenza A virus (IAV)-induced weight loss, impairment of blood oxygenation, lung edema, and endothelial/epithelial apoptosis associated with IAV infections. In addition, anti-EMAPII therapy provides a novel complementary treatment strategy to existing anti-viral and anti-inflammatory approaches.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: January 26, 2021
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Natalia Bogatcheva, Matthias Alexander Clauss, Keith L. March
  • Patent number: 10870699
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: December 22, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Aaron Sato, Ryan Stafford, Junhao Yang
  • Patent number: 10858417
    Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 8, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Patent number: 10835619
    Abstract: Provided herein is a tumor associated macrophage (TAM)-targeting liposome. The liposome has a lipid bilayer, a targeting agent associated with the lipid bilayer, and a repolarizing agent associated with the lipid bilayer. The targeting agent optionally comprises an antibody or fragment thereof that selectively binds a TAM, whereas the repolarizing agent repolarizes the TAM upon binding of the TAM by the targeting agent. Also provided is a pharmaceutical composition comprising the TAM-targeting liposomes and a method of treating a subject with cancer with the compositions or liposomes described herein.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 17, 2020
    Assignee: Verily Life Sciences LLC
    Inventors: Stephen Morton, Graziella Solinas
  • Patent number: 10781264
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 22, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Patent number: 10780120
    Abstract: The present disclosure provides modified immune cells (e.g., modified T cells) comprising a chimeric antigen receptor (CAR) having affinity for a prostate-specific membrane antigen (PSMA) (e.g., human PSMA). The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor. The present disclosure provides modified immune cells (e.g., modified T cells) comprising a CAR having affinity for PSMA and a dominant negative receptor and/or a switch receptor, wherein the modified cell is capable of expressing and secreting a bispecific antibody.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 22, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Szu Hua Sharon Lin, Xiaojun Liu, Anne Chew
  • Patent number: 10774156
    Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: September 15, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
  • Patent number: 10738132
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Gregory L. Moore, Rumana Rashid, Matthew J. Bernett
  • Patent number: 10730934
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 4, 2020
    Assignee: Medlmmune, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang
  • Patent number: 10662244
    Abstract: The present invention relates to a method (dosage regimen) for administering a CD3×CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3×CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3×CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 26, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston, Israel Lowy, Carrie Brownstein
  • Patent number: 10662243
    Abstract: The disclosure provides a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient. The disclosure also provides a method for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising administering doses in a dosing regimen. This dosing regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The Also provided is a pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: May 26, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Bauerle
  • Patent number: 10618972
    Abstract: The present disclosure provides antibodies that specifically bind to botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/C, BoNT/D, BoNT/E, BoNT/F, BoNT/G, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 14, 2020
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Maria Consuelo Garcia Rodriguez
  • Patent number: 10611851
    Abstract: This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 7, 2020
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren, Jianlong Lou
  • Patent number: 10603359
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 31, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Patent number: 10596257
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana
  • Patent number: 10588879
    Abstract: A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: March 17, 2020
    Assignee: Aurin Biotech Inc.
    Inventors: Patrick L. McGeer, Moonhee Lee
  • Patent number: 10584162
    Abstract: Non-invasive methods are provided herein for diagnosing samples as including a fungus, including fungal infection or contamination, with specific monoclonal antibodies capable of detecting molecules associated with fungi in the sample, such as a biological or environmental sample. These molecules can be identified using various methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), or a lateral flow immunoassay.
    Type: Grant
    Filed: April 23, 2016
    Date of Patent: March 10, 2020
    Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
    Inventors: Thomas R. Kozel, Breeana Hubbard, Amanda Burnham-Marusich
  • Patent number: 10526411
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 7, 2020
    Assignee: Amgen Inc.
    Inventors: Chadwick Terence King, Gordon Ng, Shaw-Fen Sylvia Hu, Hung Nguyen, Jeannie Jung